{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-012481","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.511221+00:00","generated_at":"2026-05-20T10:01:53.522678+00:00","sec_items":["1.01","3.02","3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"GT Biopharma expands private placement to $5.95M, adds new investor Marzilli","bullets":["Increased Series L preferred offering to 6,612 shares ($5.95M) from 6,056 shares ($5.45M) via First Amendment on May 21, 2025.","Added Robert A. Marzilli as new purchaser; Majority Purchasers (Five Narrow Lane, Bristol Capital) consented.","Filed Certificate of Increase raising authorized Series L shares from 28,056 to 30,630.","Greenshoe right: Purchasers may buy up to $24.0M additional preferred stock on same terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-012481","json":"https://secwatch.observer/filing/0001641172-25-012481.json","markdown":"https://secwatch.observer/filing/0001641172-25-012481.md","text":"https://secwatch.observer/filing/0001641172-25-012481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000164117225012481/0001641172-25-012481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000164117225012481/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:01:53.522678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}